Rick Simpson Oil (RSO) in Clark County, Kentucky: The Complete Guide by OilWell Cannabis

If you’re reading this in Winchester, or anywhere across Clark County’s rolling Bluegrass hills, you’re probably searching for something real. Maybe you’re a cancer patient at Clark Regional Medical Center who heard about RSO through a support group. Maybe you’re a farmer in Strode Station whose back hasn’t been the same since the last harvest. Maybe you’re a veteran near the Clark County Fairgrounds dealing with PTSD and sleepless nights, or a spouse watching someone you love suffer through chemo treatments forty-five minutes away in Lexington. Whoever you are, you found us because you’re looking for honest answers about Rick Simpson Oil in Clark County — and that’s exactly what we’re here to give you.

We’re OilWell Cannabis, a Houston-based cannabinoid company built from the ground up on one simple promise: no snake oil, no false hope, just the best possible version of cannabis education so you can decide what’s right for you. Our formulas ship nationwide, including right here to Clark County, Kentucky — because we believe everyone deserves access to transparent, lab-tested cannabinoid medicine, whether you’re in downtown Winchester or out on the Paris Pike.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical professional — he was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. We share his story because we know folks in Clark County understand what it means to be let down by conventional medicine. Maybe you’ve driven the hour to Lexington specialist appointments only to be handed another prescription that doesn’t work. Maybe you’ve watched someone you love cycle through pain medications that made things worse. Maybe you’re one of the many Kentuckians caught in the crossfire of the opioid crisis, searching for alternatives when pills have failed. That experience — of being told “no” by a doctor, of finding relief in cannabis when nothing else worked — is universal, and it’s why Simpson’s story resonates in Winchester just as deeply as it did in Nova Scotia.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from a scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused . We’ve heard similar stories from Clark County residents — people who found that the medical system, strained as it is across rural Kentucky, simply didn’t have answers for their chronic pain or neurological symptoms.

Simpson’s interest concentrated after learning about a 1974 NIH study at the Medical College of Virginia, where THC was reported to slow tumors in mice. That study — originally intended to demonstrate harm — became foundational to Simpson’s advocacy, even though its findings were never replicated in controlled human cancer trials . We mention this because we know cancer patients in Clark County encounter this 1974 study online, often presented as proof cannabis cures cancer. It’s important to distinguish: the science is real and interesting, but the gap between mouse studies and human cancer cures is vast.

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification has been published, no biopsy confirmation exists in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil .

Important context: Simpson’s account is personal testimony, not medical evidence. The absence of clinical documentation means these events cannot be evaluated as medical proof. They are, however, historically significant as the catalyst for a global movement.

The crusade — spreading the oil

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more .

We share this because we know the desperation in Clark County. When you’re facing a cancer diagnosis and the nearest comprehensive cancer center is in Lexington, when you’re dealing with chronic pain and the opioid epidemic has made doctors hesitant to prescribe, when you’re a veteran with PTSD and the VA system is backlogged — you search for alternatives. Simpson’s free-distribution model resonated because it offered hope when institutional medicine seemed to have none.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. For many people in Clark County who discovered RSO through online forums or patient support groups, Run From The Cure was their introduction .

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005 and 2009, seizing plants and equipment. He was charged with cultivation, possession, and trafficking. Eventually facing continued legal pressure, Simpson left Canada for Europe, continuing his advocacy from Croatia and later the Netherlands . This legal conflict mirrors what many Kentuckians have faced — cannabis laws that punish people for seeking plant-based medicine while pharmaceutical companies profit from addictive alternatives.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, detailing his personal experience, oil-making process, and philosophical views .

Throughout his career, Simpson maintained that cannabis oil could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge. He framed his work as fighting institutional corruption .

Important context: Simpson’s conspiratorial framing is noted without endorsement. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance. The evidence-based assessment of his medical claims follows below.

The traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core recommendation was consuming 60 grams of concentrated cannabis oil over approximately 90 days. He described this as a cancer treatment protocol, though he recommended it for numerous conditions. This protocol was designed around crude, single-strain extract with no standardized potency.

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over roughly 90 days. Simpson considered this the minimum necessary for serious cancer treatment.

Titration schedule

• Week 1: Begin with a dose the size of half a grain of rice — roughly 10-15 mg of oil — taken three times daily. Total daily intake: approximately 30-45 mg. Simpson emphasized starting small to allow the body to adjust to THC’s psychoactive effects.
• Weeks 2-5: Double the dose approximately every four days to build THC tolerance gradually. By the end of this period — roughly four to five weeks — the target is approximately 1 gram (1,000 mg) of oil per day, divided into three doses.
• Weeks 5-12: Maintain approximately 1 gram per day, divided into three doses of roughly 333 mg each, until all 60 grams are consumed.

For Clark County residents considering this protocol, it’s critical to understand: this dosing was designed for crude, unstandardized oil. The potency varied wildly depending on starting plant material. When you’re dealing with something as serious as cancer treatment, variability is dangerous.

Administration methods

• Primary — oral: Simpson recommended placing the dose under the tongue (sublingual) or swallowing it. He considered oral ingestion essential for systemic absorption and primary treatment of internal cancers.
• Secondary — topical: For skin cancers and external lesions, Simpson recommended applying oil directly, covering with a bandage, and changing every three to four days. He combined topical with oral dosing for skin cancers.
• Not recommended — inhalation: Simpson didn’t recommend smoking or vaporizing as primary treatment, though he acknowledged inhalation for immediate symptom relief (pain, nausea).

Tolerance and psychoactive effects

Simpson maintained that patients develop significant THC tolerance within three to four weeks. He considered euphoric, sedating, or disorienting effects minor and temporary, urging patients not to let the high discourage them. He recommended initial doses at night to sleep through early psychoactive effects and warned against driving during titration.

For our Clark County friends who need to work, drive, or care for family, this presents a real challenge. That’s why OilWell’s approach is fundamentally different — we preserve THCa in its non-psychoactive form so you can function during the day.

Post-protocol maintenance

After completing 60 grams, Simpson recommended 1-2 grams per month indefinitely for long-term health and cancer prevention.

Dietary and lifestyle recommendations

Simpson advocated reducing sugar, avoiding processed foods, and improving overall nutrition, though his dietary advice was general compared to his detailed oil protocol.

Important context for evaluating this protocol

This protocol was designed by one person based on personal experience. It was not developed through clinical trials, dose-finding studies, or formal research. Critical points:

• No controlled trial validation. No published randomized controlled trials, cohort studies, or well-documented case series evaluate this specific 60-gram/90-day protocol for any condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes single-strain, THC-dominant extract with no standardized potency. Actual THC content varied wildly.
• Very high THC exposure. At peak dosing, patients consumed roughly 1 gram of high-THC oil daily. Assuming 60-90% THC, that’s 600-900 mg of delta-9 THC per day — far exceeding anything studied clinically. For context, FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5-20 mg per day.
• Real risks at these doses. Consuming 600-900 mg of THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in our General Knowledge section [1][13][14][15].
• Oncology context. Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as primary treatment — potentially instead of proven therapies — introduces harm beyond the oil itself.

For Clark County cancer patients facing treatment at Clark Regional Medical Center or making the drive to Lexington’s Markey Cancer Center, we cannot stress this enough: this protocol has never been clinically validated. Delaying proven treatment for an unproven protocol can have irreversible consequences.

What is traditional Rick Simpson Oil — the product

Traditional RSO refers to the specific concentrated cannabis oil Simpson made and advocated for. It was defined by his method and materials, not by lab specifications or regulatory standards.

Source material

Simpson used high-THC, indica-dominant cannabis strains. He grew his own or sourced from trusted growers. There was no strain standardization — starting material varied by availability and growing season. For Clark County residents, this variability is a major problem. When you’re dealing with cancer or chronic pain, you need consistency, not batch-to-batch guessing.

Extraction solvent

Simpson originally used naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol. Neither is food-grade. He warned against using butane or acetone. This is one of the most significant safety concerns with traditional RSO.

Here in Clark County, where many folks have experience with agricultural chemicals and understand solvent risks, this should raise red flags. Naphtha may contain benzene, toluene, and other toxic or carcinogenic compounds. Incomplete solvent purging is difficult to verify without lab testing.

Extraction process

1. Dry cannabis placed in a container (typically a bucket)
2. Covered with solvent and agitated to dissolve cannabinoids
3. Solvent poured off through filter (cheesecloth)
4. Process repeated with fresh solvent
5. Combined solvent washes placed in rice cooker
6. Solvent evaporated at relatively low heat
7. Thick, dark oil remains
8. Transferred to oral syringes

This process is still replicated by DIY makers across Kentucky. We present it as historical documentation, not a recipe to follow — because our open-source formula (detailed later) is the modern, safer alternative.

Appearance and physical characteristics

Traditional RSO was nearly black, thick, tar-like, with strong cannabis odor and possible solvent-residual smell. It was sticky and difficult to handle at room temperature but more fluid when warmed.

If you’ve encountered homemade RSO in Clark County, you know this description. The visual and sensory contrast with OilWell’s modern MCT oil-based product is stark.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. Heat converted essentially all THCa to delta-9 THC. Traditional RSO was activated, THC-dominant.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG the source strain contained were present at natural ratios, but not controlled, measured, or targeted.
• No ratio control. Profile was entirely determined by genetics and growing conditions.
• Estimated THC content. Likely 60-90% total THC by weight, though never lab-verified.

Terpene content

Minimal to none. The combination of solvent extraction and high-heat evaporation stripped traditional RSO of terpenes. This is a significant distinction from modern formulations that preserve terpenes.

Standardization and testing

None. Every batch was different. No Certificate of Analysis, no cannabinoid quantification, no contaminant screening. Simpson operated before cannabis legalization and standardized lab-testing infrastructure.

Residual solvent risk

Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha may contain benzene, toluene, xylene, and other toxic compounds. Incomplete purging leaves potentially harmful residues. Modern extraction uses food-grade ethanol or supercritical CO₂ specifically to address this problem.

For Clark County residents, especially those with agricultural or chemical backgrounds, this solvent risk is not abstract — it’s about what you’re putting in your body.

Simpson’s claims vs. the evidence record

Simpson claimed RSO could cure cancer and many other diseases. He was adamant, consistent, and public about these claims throughout his advocacy career .

Important context for Clark County readers: We evaluate these claims using the same rigorous standards applied throughout this document because you deserve honesty, not hype.

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted results to peer review. His evidence base consisted of personal experience, self-reported patient outcomes, and informally gathered testimonials — with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature exists and is scientifically interesting:

• In vitro studies show THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines .
• Animal models show some tumor-growth inhibition in mice and rats .
• These findings generate legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro/animal results and human clinical outcomes is vast.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been exploratory, small, and have not produced results supporting cancer-cure claims .

Institutional positions

• U.S. National Cancer Institute (NCI): Acknowledges cannabinoids have been studied for potential anticancer effects in lab and animal models but does not endorse cannabis or cannabis oil as cancer treatment .
• U.S. Food and Drug Administration (FDA): Has not approved any cannabis plant product for cancer treatment. Only Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting are FDA-approved [1].
• Health Canada: Has never approved RSO or cannabis oil as a cancer cure.
• NCCIH: States the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea/vomiting, and HIV/AIDS appetite issues — not cancer cure [1].

For Clark County residents pursuing treatment at Clark Regional Medical Center or the UK Markey Cancer Center in Lexington, these institutional positions matter. RSO is not a replacement for proven oncologic therapies.

What Simpson got right

Simpson drew attention to cannabinoids as a serious biomedical research area when most of the world ignored it. His advocacy helped create the political, cultural, and social conditions for the legal cannabis industry and research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO remains the most recognized name for full-spectrum cannabis extract.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it’s not supported now. Encouraging cancer patients to rely on RSO as primary treatment — potentially instead of proven therapies — carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative-medicine literature. Simpson’s absolute certainty about curative claims, while understandable from personal experience, exceeded what the evidence could support.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly across the legal cannabis industry. Many products labeled RSO bear little resemblance to Simpson’s original oil. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract in a syringe, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic .

Simpson himself has been critical of commercial products using the RSO name while departing from his method and philosophy. His model was anti-commercial — he gave oil away free and urged people to make their own. The modern industry commercialized what he distributed freely. Whether that represents improvement (quality control, testing) or betrayal (profit, gatekeeping) depends on perspective.

What is not disputed is that modern RSO has evolved substantially, and those changes directly benefit Clark County residents.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

For Clark County residents, this comparison is crucial. When you see “RSO” online or at a shop in nearby Lexington, you need to know what you’re actually getting. Most products bear little resemblance to Simpson’s original, and that’s actually a good thing — if they’re made with modern safety standards.

Why OilWell’s formulas diverge from traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the tradition but depart deliberately:

Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. OilWell includes seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

Terpene preservation and addition. Traditional RSO had essentially no terpenes. OilWell includes live terpenes at 5% with a specific seven-terpene profile — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation remains developing [20][21][23][24][25][26][27][28][29].

THCa as a separate ingredient. Traditional RSO fully decarboxylated everything. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity lost when THCa converts to THC [12].

Reduced delta-9 THC dominance. Traditional RSO was 60-90% delta-9 THC. OilWell’s formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing remaining cannabinoids across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects broader cannabinoid research rather than single-compound dominance.

Product format innovation. Simpson envisioned only oral oil from a syringe. OilWell offers both 30 mL sublingual oil and 1-gram vape cartridge, each with format-specific formulation acknowledging different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO used naphtha or isopropyl alcohol — neither food-grade. Naphtha is a petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other toxic compounds. Incomplete solvent purging is difficult to verify without analytical equipment.

Modern cannabis extraction uses food-grade ethanol or supercritical carbon dioxide (CO₂). These allow much more complete solvent removal, and finished products can be tested for residual solvents using validated methods like headspace gas chromatography. This is one of the most straightforward improvements modern regulated cannabis has made over traditional RSO.

For Clark County residents with chemical sensitivity or concerns about product purity — especially important for cancer patients with compromised immune systems — this evolution matters profoundly.

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker (60-80°C for naphtha, ~82°C for isopropyl alcohol) converted essentially all THCa to delta-9 THC. The finished oil was activated, THC-dominant, and always psychoactive.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is intentional, informed by the THCa evidence profile showing potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism that is lost when THCa converts to THC [12].

For Clark County residents who need to work, drive, parent, or function during the day, this distinction is everything. You can use the product raw for non-psychoactive benefits or decarboxylate at home for full psychoactive potency. The choice is yours.

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with low boiling points (21-157°C). Most cannabis terpenes volatilize below 180°C. Traditional RSO destroyed terpenes in two ways: dissolving them into solvent, then evaporating them off during high-heat removal.

Traditional RSO was essentially cannabinoid-only, despite deriving from terpene-rich plant. Whatever aromatic or potentially bioactive terpenes the source cannabis contained were lost.

OilWell’s formulas specify live terpenes at 5% with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each has its own evidence profile in our General Knowledge section. The entourage-effect literature [20][29] provides theoretical framework for why preserving terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof remains limited.

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began in the early 2000s, cannabis was illegal in Canada and most of the world. No regulatory framework existed for cannabis products, no standardized testing, no legal pathway for clinical research, no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point; personal experience was the primary evidence currency.

Simpson’s methods reflected those constraints. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This isn’t necessarily a moral failing — it’s a description of the environment.

This document takes a fundamentally different approach. Our General Knowledge section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature when human data are sparse [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled.

We honor the historical origin of RSO while committing to modern cannabinoid science standards. Where Simpson relied on personal testimony, we rely on published literature and institutional sources.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison with modern, standardized, multi-cannabinoid formulation is not straightforward — the products are fundamentally different.

Key differences:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60-90% delta-9 THC. OilWell’s formula distributes 16,590 mg across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg) — a completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. OilWell’s includes live terpenes at 5%, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol delivered approximately 600-900 mg of delta-9 THC per day at peak dosing. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making per-dose delta-9 THC exposure dramatically lower.

Dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by per-compound evidence in our General Knowledge section and responsible titration principles accounting for each cannabinoid’s safety profile.

References for this section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. While we’re based in Houston’s Montrose neighborhood, our commitment to accessibility means we serve customers nationwide — including right here in Clark County, Kentucky. Colin grew up in McAllen, Texas, right across the river from Reynosa, Tamaulipas, Mexico — one of the most economically challenged and dangerous regions along the U.S.-Mexico border. That upbringing shaped everything about OilWell’s philosophy.

Colin’s childhood was marked by exposure to both opportunity and violence. By sixteen, he’d faced every form of violence imaginable. Many of his best friends have been killed or are in prison. He learned to hustle early, taking on risky work transporting items across the border. Those experiences exposed him to the complexities and dangers of life in that region — not so different from the economic challenges facing many working families in Clark County.

Despite the dangers, Colin did not fall into selling harder substances. He focused on cannabis, seeing it as safer and more beneficial. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — defines OilWell’s approach.

The company’s origin story begins with a dog named Bentley. Bentley was more than a pet — he was family. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up wasn’t an option. Colin had already faced too much loss. Bentley was a fighter, just like him. In a desperate search for alternatives, a rescue worker named Jessica asked a question that changed everything: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience — but it was recreational. He’d never explored therapeutic applications. Determined to save Bentley, he learned to create CBD golden paste, a specialized cannabinoid formula for pets. It wasn’t a cure, but it was hope. And that hope delivered what veterinary medicine said was impossible: Bentley got up, walked over, and brought Colin his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo — dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone couldn’t address neurodegeneration, dementia, glaucoma, and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into cannabis beyond getting high. It became a mission to create real solutions that alleviate pain and suffering, not just for pets but for people. Bentley’s story is OilWell Cannabis’s foundation, driving our commitment to quality, innovation, and compassionate care.

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to quit Xanax, he did it cold turkey — notoriously difficult and dangerous — using the cannabinoid knowledge he’d developed keeping Bentley alive. The Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits Colin first discovered through Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 KTRK Houston — Houston’s number-one news source — featured Colin Valencia and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Colin’s quote from our first ABC13 feature in September 2019 captures our philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). We’ve been operating since 2019, generate approximately one million dollars in annual revenue, maintain a near-5.0 Google rating, and are Texas DSHS licensed. Our products are not mass-produced — they’re carefully crafted with personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only our own recipes and ideas. Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in deliberate, evidence-motivated ways that solve the problems limiting Simpson’s original vision.

Four core principles define our approach:

1. Accessibility over gatekeeping. No medical card required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally — even in Clark County, Kentucky, where medical cannabis remains unavailable.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their medicine; we engineered a product that puts that control in your hands through chemistry.

3. Open-source formulas. We publish our complete formulas publicly — every cannabinoid, every milligram, every percentage — so that anyone who cannot afford our products can source ingredients and make their own. Simpson gave his oil away free and taught people how to make it; we adapted that ethos for the modern marketplace by selling a professionally manufactured, lab-tested, standardized product and publishing the recipe.

4. Evidence-informed, not evidence-overstating. Our General Knowledge section represents our commitment to honest education about what science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; we have that access and use it to distinguish what is well-supported, what is emerging, and what is overstated.

Farm Bill compliance and the THCa legal framework — crucial for Kentucky

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of OilWell’s RSO product design and is particularly significant for Clark County residents.

Kentucky context: As of 2025, Kentucky has no comprehensive medical marijuana program. The state legalized hemp-derived CBD in 2017 but has not authorized medical or recreational cannabis. This means Clark County residents cannot access medical cannabis through state dispensaries. However, the Farm Bill provides a legal pathway for hemp-derived products nationwide — including here in Kentucky.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle — 3 milligrams per milliliter — well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and can be shipped to your door in Winchester, Clay City, or anywhere in Clark County.

THCa (tetrahydrocannabinolic acid) is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance for Clark County residents is substantial. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC, this produces approximately 1,405 milligrams of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). You control the decision. The product is legal everywhere all component cannabinoids are legal, which enables shipping to jurisdictions with compatible hemp laws — including Clark County, Kentucky.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, and receipts. Kentucky residents should be aware that while hemp-derived products with less than 0.3% delta-9 THC are legal under federal law, state interpretations may vary. We provide complete documentation for your records.

Open-source formulas — why OilWell publishes everything

OilWell publishes our complete RSO formulas publicly — every cannabinoid, every milligram, every percentage — so that anyone who cannot afford our products can see exactly what the formula contains, source individual cannabinoid distillates and isolates, and make their own version. The formulas in our RSO Sublingual Oil and RSO Vape Cartridge sections are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Our open-source philosophy didn’t start with RSO — it started with Bentley. On our About Us page, we published the actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing a similar crisis could make it themselves:

CBD golden paste recipe for pets — the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix turmeric and water. In a saucepan, combine turmeric powder and water, stirring over low heat until thick paste forms (7-10 minutes). Add more water if too thick.
2. Add coconut oil and pepper. Once paste is thick, add coconut oil and freshly ground black pepper. Stir until thoroughly mixed.
3. Cool and store. Allow to cool, transfer to jar with lid, refrigerate up to two weeks.
4. Dosage. Add small amount of CBD oil to paste before giving to pet, adjusting based on weight and health needs. Start low and gradually increase.

Serving suggestion: Mix small amount of golden paste with pet’s food once or twice daily. Monitor for changes and consult veterinarian if concerns arise. Always consult veterinarian before starting any new supplement regimen.

This recipe — published for free, years before our RSO formulas were open-sourced — demonstrates that the pattern is consistent. We gave away the formula that saved Bentley before we gave away the formula for people. The open-source ethos is not a marketing strategy. It is foundational behavior.

The decarboxylation choice — patient-controlled potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa to delta-9 THC, leaving the patient with no choice about psychoactivity — the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1 — Raw, no heat. All 1,500 mg stays as THCa — completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving, and daytime use with zero psychoactive impairment — ideal for Clark County residents who need to stay functional for jobs, family care, or operating farm equipment.

Option 2 — Fully activated, home decarboxylation. Heating oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container converts 1,500 mg THCa to approximately 1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC, this yields approximately 1,405 mg total delta-9 THC. Combined with 6,000 mg delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO — 100% legally, because decarboxylation occurs at your discretion after purchase. You may also transfer a controlled portion to a second oven-safe container, decarboxylating only what you intend to use while preserving remainder in raw THCa form.

Option 3 — Vape, auto-decarboxylation. Our RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule.

This design puts potency decision entirely in your hands — aligning with Simpson’s principle that patients should control their medicine, but implementing it through actual product chemistry rather than one-size-fits-all approach.

Solvent-free production

OilWell’s RSO is not a traditional extraction product. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in controlled production. No naphtha. No isopropyl alcohol. No butane. No extraction solvents in the finished product.

This approach eliminates residual solvent risk — one of the most significant safety concerns with traditional RSO production, as discussed in our Rick Simpson section.

The product uses organic MCT oil (medium-chain triglycerides) as carrier base. MCT oil is food-grade lipid carrier facilitating cannabinoid absorption through sublingual tissue and providing neutral taste — significant improvement over tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our OilWell website.

For Clark County residents concerned about product purity — especially important for cancer patients, immunocompromised individuals, or those with chemical sensitivities — this testing provides transparency traditional RSO could never offer.

The broader OilWell product portfolio

Beyond RSO, OilWell produces a range of cannabinoid products, each developed from formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach — our most popular product. A carefully formulated experience providing euphoric, long-lasting sensation, particularly favored by veterans for relieving pain and PTSD symptoms without being overly aggressive. Given Kentucky’s significant veteran population, this product resonates with those who’ve served.

Peace Gummies — developed directly from Colin’s own PTSD and benzodiazepine addiction experience. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in vape form for quick relief — Colin personally uses the vape to manage his insomnia and severe PTSD. For Clark County residents dealing with anxiety, addiction recovery, or sleep disorders, this represents real-world validation.

Custom creations — we offer custom-made products tailored to individual needs. Whether specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, we design targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two product formats

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900+ mg total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

Complete RSO Guide — full product guide with science, competitive analysis, protocols, and ordering information.

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

For Clark County residents with active lifestyles — whether working the land, commuting to Lexington, or managing family responsibilities — this flexibility is essential. Use raw sublingual during the day for functional relief without impairment; use decarboxylated sublingual or vape at night when psychoactive effects are desired or sleep support is needed.

Competitive comparison — OilWell RSO vs. alternatives

OilWell RSO vs. traditional dispensary RSO (where legal)

Dimension	Traditional Dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until heated by customer
Access requirements	Medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Ships directly to Clark County, Kentucky
Farm Bill compliant	No — state medical cannabis program	Yes — less than 0.3% delta-9 THC

For Clark County residents, the access difference is profound. With no Kentucky medical cannabis program, you cannot get dispensary RSO legally. OilWell’s Farm Bill-compliant formula ships directly to your door.

OilWell RSO vs. hemp CBD RSO products

Dimension	Typical Hemp CBD RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to ~1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes — via THCa decarboxylation and delta-8 THC
Approximate price	$40-50	$129.99

The value proposition for Clark County residents is clear: 16.5 times more total cannabinoids, multiple minor cannabinoids present at therapeutically relevant levels, and the option for psychoactive effects — all delivered legally to Kentucky.

Condition-specific usage context

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in our General Knowledge section and our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not substitutes for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, take medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea/vomiting evidence [1][13], CBD anxiolytic buffering [3]

For Clark County residents making the drive to Lexington for cancer treatment, having a fast-acting option for breakthrough nausea can make the journey more manageable.

Chronic pain (fibromyalgia, arthritis, neuropathy)

• Daytime: 0.3-0.5 mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Given Kentucky’s opioid crisis and the challenges many Clark County residents face accessing pain management specialists, having a non-psychoactive daytime option is significant.

Sleep support

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN — the dosage investigated in 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN — above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

For Clark County residents dealing with insomnia — whether from chronic pain, PTSD, or other conditions — this offers a research-informed approach.

Anxiety and stress

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

In a community like Clark County, where mental health resources can be limited and stigma around mental illness persists, having a functional daytime option matters.

General titration principle: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and global accessibility — shipping to Clark County, Kentucky

OilWell operates the only same-day RSO delivery system in Houston. While we can’t offer same-day delivery to Clark County (that’s a 900-mile drive!), we do offer nationwide shipping that brings our products directly to your door in Winchester, Clay City, or anywhere in Clark County.

Nationwide shipping to Kentucky

• All 50 states where Farm Bill-compliant products are legal — including Kentucky
• USPS Priority Mail (2-3 business days), FedEx and UPS Ground (3-5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments
• Signature-required option available

For Clark County residents accustomed to driving to Lexington or Louisville for specialized products, having direct-to-door shipping is a major convenience. No need to explain your purchase to a pharmacist or worry about local stigma.

International shipping

OilWell ships internationally and has delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3% delta-9 THC at point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

• All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• Minimum flat-fee shipping applies; excessive international shipping costs are billed to customer
• Customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk
• Contact: (832) 416-2816 or [email protected]

The significance of international access cannot be overstated. Rick Simpson could not ship his oil anywhere — it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Germany, a chronic pain patient in Australia, or a veteran in the United Kingdom can now access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. OilWell built a product that can move across borders legally — completing a piece of Rick Simpson’s vision that prohibition made impossible.

OilWell’s PANDEM1C SEO technology — a proprietary system with 14 million distinct geopolitical locations in its database and over 300 AI models — drives organic search visibility across six continents, making OilWell products discoverable to international patients searching for RSO in their own language.

How the OilWell formulas connect to the evidence in this document

Every cannabinoid in OilWell’s formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — has its own evidence profile in our General Knowledge section. Every terpene — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — is covered with preclinical and review-level evidence.

The formulas published in this document are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to current evidence. Where our RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides source evaluation context — the same peer-reviewed citations, evidence-tier assessments, and cautious interpretation framework.

Our General Knowledge section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to our own products. This document does not exempt OilWell from the same evidence standards applied to the broader cannabinoid field. That is intentional. Our position — as stated by Colin Valencia in 2019 — is that people deserve the best possible version of information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

OilWell Cannabis is more than a brand — it is a promise to our customers that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. And as we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that has defined us from the day Bentley got up, walked across the room, and brought his ball to play.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia — Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK) — serving America’s fourth-largest city — featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or breadth.

For Clark County residents evaluating our credibility, this matters. When a major-market ABC affiliate repeatedly identifies someone as the most credible, quotable, accessible voice in the legal cannabis industry, that recognition cannot be purchased — it can only be earned.

Feature: Texas CBD businesses booming as industry continues to evolve — September 15, 2019

Source: ABC13 Houston (KTRK)
Reporter: Tom Abrahams

This earliest documented ABC13 feature captured the moment CBD went mainstream in Texas. The segment’s description noting CBD was being pitched “for every member of the family, including pets” foreshadowed the broad-spectrum consumer education approach Colin would build.

Colin’s foundational quote from this broadcast: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This quote — from 2019, years before our current formulas were published — is the seed of everything OilWell became. The open-source formula publication, evidence-based research documentation, refusal to make unsupported claims: it all traces here.

Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts — March 22, 2021

Source: ABC13 Houston (KTRK)
Reporter: Tom Abrahams

This feature established Colin’s role as ecosystem builder, helping other entrepreneurs like Jonathan Pina enter legal cannabis. His therapy quote — “pain comes in a lot of different forms” — went deeper than prior interviews. For Clark County residents dealing with physical pain, emotional trauma, or the ripple effects of addiction, this framing resonates.

Feature: What is Delta 8 THC and why is it considered legal weed in Texas — May 24, 2021

Source: ABC13 Houston (KTRK)
Reporter: Steve Campion

This investigative feature became one of ABC13’s most referenced cannabis segments. The exchange — “Maybe you want to get high” — became iconic: radical honesty on mainstream television. The piece balanced Colin’s stance with medical caution from Dr. Michael Weaver and regulatory advocacy from Heather Fazio. The full DEA statement documented federal ambiguity that allowed the market to exist.

For Clark County residents, this feature explains the legal landscape that makes our THCa-based products possible. The same framework that allowed Delta-8 to exist now enables legal THCa products that you can convert at home.

Feature: Houston CBD shop giving away free products to those who get COVID vaccine — August 20, 2021

Source: ABC13 Houston (KTRK)

OilWell gave away approximately $35,000 in product (1,000 caviar pre-rolls at $34.99 each) to encourage COVID-19 vaccination. We coordinated with the city of Houston, hosted at HydroShack Hydroponics, with no political strings attached.

For Clark County residents, this demonstrates our community-first philosophy is real — not hypothetical. When public health crisis required action, we committed real product and real coordination with city government.

Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality — October 19, 2021

Source: ABC13 Houston (KTRK)
Reporter: Shelley Childers

When Texas reclassified Delta-8 as Schedule I overnight, Colin had already removed all Delta-8 products from shelves — proactively, before enforcement. He tried to warn other operators unknowingly shipping Schedule I narcotics. Zachary Maxwell’s context — veterans with PTSD, $50M Texas market, felony penalties for a single vape cartridge — made stakes viscerally clear.

This demonstrates our character: willingness to absorb major revenue loss, act ethically ahead of enforcement, and position as expert guide for industry in crisis rather than victim of regulation.

Feature: Biden marijuana pardon — experts weigh in on why Texas won’t see impact — October 7, 2022

Source: ABC13 Houston (KTRK)
Reporter: Nick Natario

This feature revealed Colin’s personal marijuana conviction history. This transforms the entire media record. Every feature, every quote about therapy, education, not selling snake oil — all carry additional weight when you understand the person saying it has personally experienced cannabis criminalization consequences.

For Clark County residents, many of whom have seen friends or family affected by Kentucky’s strict cannabis laws, this personal history makes our commitment to legal, transparent access even more meaningful.

Feature: Marijuana industry getting creative as Texas laws continue to change — April 21, 2023

Source: ABC13 Houston (KTRK)
Reporter: Nick Natario

Colin’s “Renaissance” framing reframed the present as opportunity rather than waiting. Nico Richardson’s comparison (Texas 10,000 active patients vs. Florida 700,000 with two-thirds the population) and his Advil dosing analogy provided industry context. HB1805’s passage and $3.7 billion tax revenue from legal states gave national scope.

For Clark County residents, this positions OilWell at the frontier — the company leading the industry as laws evolve.

Complete index of all Colin Valencia quotes across all ABC13 features

(Chronological order preserved as in original document)

September 15, 2019 (CBD Business Boom):

1. “It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

March 22, 2021 (Decriminalization/Jonathan Pina):
2. “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

May 24, 2021 (Delta-8 THC “Legal Weed”):
3. “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

August 20, 2021 (COVID Vaccine Giveaway):
4. “We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”
5. “[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.”

October 19, 2021 (Delta-8 Ban):
6. “It’s going to be a surprise to a lot of people.”
7. “It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.”
8. “So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
9. “It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”

October 7, 2022 (Biden Marijuana Pardon):
10. “You face challenges with housing, loans, and banking, I mean with about everything.”
11. “I would love to see people not get hurt for this anymore.”

April 21, 2023 (Texas Marijuana Laws 4/20):
12. “I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
13. “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

Key facts and details from the media record

About Colin Valencia and OilWell Cannabis:

• Colin Valencia is owner of OilWell Cannabis (OilWell CBD in earlier articles)
• Has previously faced charges for marijuana possession (revealed October 2022 Biden pardon feature)
• The OilWell dispensary is located in southwest Houston
• Specializes in hemp-derived CBD and THC products
• Described as local wholesaler in 2019; by 2022 preparing to debut CBD vending machine
• Products sold at HydroShack Hydroponics on West 20th Street in The Heights
• Partnered with The Game on special edition Delta-8 caviar comet rock pre-rolls (COVID vaccine feature)
• Gave lift to Jonathan Pina’s High Maintenance Edibles mobile vendor concept (decriminalization feature)
• Gave away 1,000 special edition caviar pre-rolls (valued at $34.99 each = approximately $35,000 in product) to encourage COVID vaccination
• Contacted city of Houston to help coordinate vaccination efforts
• Proactively removed all Delta-8 products when ban announced and tried to warn other operators

ABC13 reporters who covered OilWell:

1. Tom Abrahams — September 2019 and March 2021
2. Steve Campion — May 2021
3. KTRK Staff — August 2021
4. Shelley Childers — October 2021
5. Nick Natario — October 2022 and April 2023

The through-line — what the media record reveals

These seven ABC13 features and one YouTube clip tell a story no single article could capture:

Consistency across years. Colin appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. The cannabis industry in Texas changed dramatically during those years — legal CBD went from gray area to booming business, Delta-8 went from unknown to $50M market to Schedule I overnight, a president pardoned federal marijuana convictions, and state legislators debated medical expansion. Through every shift, ABC13 returned to Colin as primary source.

Breadth of expertise. Features span business reporting, consumer health education, product investigation, legal analysis, political commentary, and community health advocacy. No other Houston cannabis figure was asked to speak to that range across that many segments.

Community action. The COVID vaccine giveaway — $35,000 in product, coordination with city government, no political strings — is documented evidence of community-first philosophy. So is Colin’s decision to proactively remove Delta-8 products and warn other operators before enforcement began.

Personal stakes. The October 2022 revelation that Colin has personal marijuana conviction history transforms the entire media record. Every feature, every quote about therapy, education, not selling snake oil — all carry additional weight when you understand the person saying it has personally experienced cannabis criminalization consequences.

Evolution of language. In 2019, ABC13 called the business “OilWell CBD, a local wholesaler.” By 2021, the reports described OilWell Cannabis as a dispensary and featured Colin as industry authority. By 2023, Colin was explaining industry dynamics and legal strategy on camera with confidence of sector leader.

These features are not marketing materials. They are independently produced, editorially controlled news segments from major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, quotable, accessible voice in Houston’s legal cannabis industry. That is recognition that cannot be purchased — it can only be earned.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters because the evidence base is uneven. Of compounds listed, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes remain more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

Institutional baseline from NIH and related sources

• NCCIH states the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea/vomiting, and appetite/weight-loss indications associated with HIV/AIDS. It notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research [1].
• NCCIH emphasizes FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns highlighted by NIH include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns [1].
• NCCIH specifically warns over-the-counter CBD products may differ from labels and that CBD has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions [1].

Cannabinoids

CBD

• Evidence profile: Strongest human evidence in current formula set, especially when studied as purified product rather than loose wellness ingredient [1]-[6].
• Best supported: Purified CBD has most credible human evidence in seizure disorders, clearest major-example indication acknowledged by institutional and peer-reviewed literature [1][2].
• Anxiety research: 2024 systematic review and meta-analysis covering 316 participants across eight articles reported statistically significant anxiolytic signal, but authors stressed clinical sample remains limited and more trials needed before broad conclusions justified [3].
• Pain research: 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded pain literature is promising but heterogeneous, with trial quality and consistency limiting confidence in broad analgesic claims [4].
• Sleep research: 2023 insomnia review found literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments [5].
• Safety and interaction concerns: 2023 systematic review and meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions as important considerations [1].
• Bottom line: CBD is most evidence-developed nonintoxicating cannabinoid, but even here strong evidence is concentrated in few specific indications rather than broad wellness claims [1]-[6].

CBG

• Evidence profile: Mostly review-level and preclinical; human evidence remains sparse [7][8].
• Pharmacology: CBG is biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, making it mechanistically interesting but not yet clinically established [7].
• Potential research areas: Published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions [7][8].
• Caution: 2021 pharmacology review notes CBG is already being sold commercially while evidence base remains thin, meaning claims frequently outrun science [7].
• Bottom line: CBG is serious research topic, but at present should be described as promising minor cannabinoid with limited clinical validation rather than proven therapeutic cannabinoid [7][8].

Delta-8 THC

• Evidence profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC [9]-[11].
• Comparative pharmacology: 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is partial CB1 agonist with cannabimimetic activity in animals and humans, but appears less potent than delta-9 THC, likely in part because of weaker CB1 affinity [9].
• Public-health literature: 2023 scoping review found much of delta-8 evidence base still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. Same review noted reports of adverse consequences and emphasized regulatory and product-quality concerns [10].
• Manufacturing context: Recent chemistry and pharmacology review reinforces commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter [11].
• Bottom line: Delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11].

THCa

• Evidence profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence [12].
• What it is: THCa is acidic precursor of THC and may represent large share of THC-related content in raw plant material. Key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing [12].
• Psychoactivity: Major review source stresses THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays in acidic form and is not substantially decarboxylated [12].
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].
• Bottom line: THCa is best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC [12].

Delta-9 THC

• Evidence profile: Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15].
• Institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea/vomiting, appetite/weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while stressing many other uses remain uncertain or early-stage [1].
• Pain evidence: 2022 systematic review of cannabis-based products for chronic pain found products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].
• Pharmacokinetics and onset: Classic pharmacokinetic review remains useful: inhaled THC produces effects within seconds to minutes, peaks roughly within 15-30 minutes, and tapers over few hours; oral THC has later onset, later peak, and longer duration, which matters for both benefit and overconsumption risk [14].
• Mental-health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings [15].
• Broader safety: Institutional and review literature also describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns in THC-containing products [1][14][15].
• Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings, but also carries clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15].

CBN

• Evidence profile: Weak human evidence; marketing has clearly moved ahead of data [12][16][17].
• What it is often marketed for: Sleep and sedation. That reputation is widespread, but clinical support is far thinner than market suggests [16][17].
• Best direct review for sleep claim: 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16].
• Broader sleep literature: 2024 updated review on cannabis and sleep concluded overall cannabinoid sleep research still does not match scale of real-world use, and need for better-designed, adequately powered trials remains substantial [17].
• Chemical context: Downstream cannabinoid degradation pathways matter; review literature on THCa notes THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts [12].
• Bottom line: CBN is one of clearest examples where cultural reputation is stronger than current clinical evidence base [16][17].

CBC

• Evidence profile: Emerging, intriguing, and still overwhelmingly preclinical or review-based [18][19].
• Pharmacology and therapeutic interest: 2024 focused review on CBC argues it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18].
• What older literature shows: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims [19].
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18].
• Bottom line: CBC belongs in category of scientifically credible minor cannabinoids that deserve more research, not category of already-validated clinical actives [18][19].

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much of terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

• Evidence profile: Largely review and preclinical, with useful safety literature [20]-[22].
• Potential activity: 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but overwhelming share of those claims comes from nonhuman or non-cannabis literature [21].
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and important in patch-testing literature [22].
• Bottom line: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22].

Myrcene

• Evidence profile: Mostly preclinical, with very limited human evidence [20][23].
• Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states human studies are lacking [23].
• Interpretation caution: Myrcene is often invoked in consumer language as if it were proven sedating terpene that explains couch-lock or sleep effects. That is stronger claim than human evidence currently supports [20][23].
• Bottom line: Myrcene is plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].

Caryophyllene

• Evidence profile: Among most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].
• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24].
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions repeatedly discussed in review literature, but human clinical confirmation remains limited [24].
• Bottom line: Beta-caryophyllene is arguably strongest candidate for terpene with cannabinoid-system significance, but it still should not be described as clinically proven for outcomes commonly attributed to it [24].

Pinene

• Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25].
• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but also emphasized well-designed clinical trials are lacking [25].
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].
• Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool

• Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
• Research summary: Linalool repeatedly discussed in relation to stress, mood, and brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing lack of robust human trials [25].
• Additional literature: Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains translational rather than definitive clinical story [26].
• Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].
• Bottom line: Linalool is scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene

• Evidence profile: Translationally interesting, but still early [20][27].
• Scoping-review findings: 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].
• Interpretation caution: Those findings are valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].
• Bottom line: Humulene is one of more interesting terpene research targets in this list, but it remains far from clinically settled [27].

Terpinolene

• Evidence profile: One of least clinically characterized terpenes in this file [20][28].
• Systematic-review findings: 2021 terpinolene review screened 2,449 records and included 57 studies, concluding terpinolene has range of reported biological effects but evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials [28].
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20].
• Bottom line: Terpinolene is biologically interesting, but among listed terpenes it remains especially underdeveloped clinically [20][28].

Research limits and interpretation

• Evidence base is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. Common error in cannabis writing is letting evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14].
• For THCa in particular, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].

Common overstatements to avoid

• Overstatement: CBN is clinically proven sleep cannabinoid.
  More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].
• Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].
• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12].
• Overstatement: Delta-8 THC is safe because it is hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical takeaways for the formulas in this document

• Most evidence-developed actives are CBD and delta-9 THC.
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• Listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

References

[1] National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026.

[2] Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238.

[3] Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049.

[4] Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438.

[5] Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229.

[6] Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752.

[7] Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212.

[8] Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471.

[9] Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933.

[10] LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028.

[11] Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249.

[12] Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130.

[13] McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153.

[14] Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360.

[15] Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440.

[16] Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371.

[17] Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727.

[18] Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213.

[19] Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364.

[20] André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543.

[21] Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566.

[22] Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12.

[23] Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666.

[24] Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639.

[25] Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211.

[26] Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092.

[27] Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674.

[28] Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768.

[29] Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5%
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg

For Clark County residents doing the math: that’s 553 mg of active cannabinoids in every milliliter. The entire bottle contains 16,590 mg total. Compare that to typical CBD products you might find in Winchester stores, which often contain 500-1,000 mg total for the whole bottle. This is clinical-strength formulation.

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%
• Format: 1 Gram cartridge

For Clark County residents seeking fast relief for breakthrough symptoms, the vape format offers 1-2 minute onset. The 510-thread compatibility means it works with standard vape batteries available locally.

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene – pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

For Clark County residents familiar with the scents of Kentucky’s forests, farms, and gardens, these terpenes create a sensory experience that connects to local environment. The pinene echoes our pine forests, linalool recalls lavender gardens, caryophyllene brings black pepper spice from your kitchen. This isn’t just medicine — it’s a sensory journey rooted in natural chemistry.

CONCLUSION: THE OILWELL PROMISE TO CLARK COUNTY

We know that if you’re reading this in Winchester, or out in the beautiful rolling hills of Clark County, you’re not looking for hype. You’re looking for hope grounded in reality. You’ve probably seen friends struggle with pain medications that stop working. You’ve watched neighbors deal with cancer diagnoses while driving hours to Lexington for treatment. You’ve heard about the opioid crisis devastating Kentucky communities and you’re searching for alternatives that actually make sense.

That’s why we’re here. We’re not a faceless corporation. We’re a company built on a man saving his dog, on surviving PTSD and benzo addiction, on giving away $35,000 in product to help people get vaccinated, and on showing up on mainstream television year after year with the same honest message: here’s what we know, here’s what we don’t, here’s the formula, you decide.

Our RSO formulas ship directly to Clark County because we believe geography shouldn’t determine access to quality cannabinoid medicine. Whether you’re in the heart of Winchester or on a farm off the Bourbon Trail, you deserve the same clinical-strength, lab-tested, transparently formulated product that patients in Houston receive.

The open-source formulas are yours to use. If you can afford our professionally crafted products, we’ll deliver them with full testing documentation and Kentucky-legal compliance. If you can’t, the recipes are published right here — use them, share them, make them your own. That’s how Bentley got up and walked. That’s how Colin quit Xanax cold turkey. That’s how we believe medicine should work.

We can’t promise miracles. We can promise transparency, quality, and respect for your intelligence. In Clark County, where self-reliance and community matter, that might be exactly what you’re looking for.

Contact us:

• Phone: (832) 416-2816
• Email: [email protected]
• Website: https://oilwellcbd.com/
• Instagram: @oilwellcbd
• Address: 810 Richmond Ave, Houston, TX 77006

We ship to Winchester, Clay City, and all of Clark County, Kentucky. Your package will arrive discreetly, with full Certificates of Analysis and legal documentation. The rest is up to you.